Merger and acquisitions activity in the North American pharma and life sciences sector continued to gain momentum in Q2 2010 ending the quarter up 32% from Q1 2010 levels with 70 announced deals in North America.
Led by Abbott’s $3.7-billion bid for Piramal’s Healthcare Solutions business, there were three deals valued over $3 billion (including Canada-based Biovail Corporation’s for Valeant Pharmaceuticals) and seven transactions valued over $1 billion in the quarter.
Improved access to deal capital has opened the door to an uptick in activity and higher values. This marked increase in M&A activity volume continues to be driven by strategic players.
Download the full report.